Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
Under the deal, Quiver will receive an undisclosed advance payment and research support
Subscribe To Our Newsletter & Stay Updated